We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 476

CADTH releases new guidelines
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • September 19 2018

The Canadian Agency for Drugs and Technologies in Health (CADTH) recently published the Procedure and Submission Guidelines for the CADTH Common Drug


You don’t need to build it for them to come: Federal Court affirms trademark “use” for services does not require bricks and mortar business in Canada
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • September 13 2018

Non-Canadian hoteliers have reason for celebration following the release of the Federal Court of Canada’s anticipated decision in Hilton Worldwide


Patented Medicine Prices Review Board releases annual report on drug market entry
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • September 12 2018

The Patented Medicine Prices Review Board recently announced the publication of the second annual edition of Meds Entry Watch 2016. The report


Patented Medicine Prices Review Board's multi-stakeholder steering committee holds first meeting
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • September 12 2018

The Patented Medicine Prices Review Board (PMPRB) has been consulting on its proposed reform of the federal price review process and associated


Alexion denied leave to appeal in case challenging constitutionality of PMPRB's remedial powers
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • September 10 2018

The Supreme Court of Canada recently dismissed Alexion Pharmaceuticals' application for leave to appeal the Federal Court of Appeal decision in


Shire's VYVANSE patent valid, prohibition order issued
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • September 3 2018

The Federal Court has granted Shire's application under the pre-amended Patented Medicines (Notice of Compliance) Regulations for an order prohibiting


Federal Court of Appeal dismisses Apotex’s appeal in judicial review of Health Canada decision seeking further information from facilities in India
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • August 29 2018

As previously reported, the Federal Court dismissed Apotex's application for judicial review of the decision of the Therapeutic Products Directorate


Patented Medicine Prices Review Board releases August 2018 NEWSletter
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • August 29 2018

The Patented Medicine Prices Review Board (PMPRB) released the August 2018 issue of its NEWSletter which includes an update on the PMPRB's


CADTH launches the CADTH Pharmaceutical Reviews Update
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • August 29 2018

The Canadian Agency for Drugs and Technologies in Health (CADTH) has launched the CADTH Pharmaceutical Reviews Update


Health Canada to implement further pre-market transparency initiatives for prescription drugs
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • August 29 2018

Health Canada announced it will move forward with Phase III of its prescription drug product transparency initiatives. Beginning October 1